Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Five Prime Therapeutics has selected BioWa and Lonza system to develop and produce multiple proprietary antibodies in FivePrime’s oncology pipeline.
Subscribe to our email newsletter
Potelligent Chok1SV which manufactures recombinant antibodies will be a host cell line.
The technology will include BioWa’s glycosylation Potelligent Technology and Lonza’s GS Gene Expression System in the development of therapeutic Antibodies.
Antibodies produced by this cell line exhibit antibody dependent cellular cytotoxicity (ADCC) and exert potent cytotoxic effects even when target antigen is low.
They also work in blood and retain all other features of common antibodies.
Lonza Development Services Head Janet White said,"We are pleased to offer the Potelligent Chok1SV Cell Line as a key component to therapeutic antibody development.”
FivePrime Vice President Michael Kavanaugh said,"The combination of the clinical validation seen with other Potelligent antibodies and the track record of the GS cell line were key to our decision to select this system to enhance the potential for therapeutic efficacy of our emerging pipeline of antibodies in oncology.”